Hoth Therapeutics (NASDAQ:HOTH) Trading Down 1.9% – Time to Sell?

by · The Cerbat Gem

Shares of Hoth Therapeutics, Inc. (NASDAQ:HOTH – Get Free Report) traded down 1.9% during mid-day trading on Wednesday . The stock traded as low as $1.00 and last traded at $1.05. 4,557,482 shares changed hands during trading, an increase of 1,536% from the average session volume of 278,491 shares. The stock had previously closed at $1.07.

Wall Street Analyst Weigh In

Several research firms recently commented on HOTH. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Hoth Therapeutics in a research report on Monday, December 22nd. D. Boral Capital reissued a “buy” rating and issued a $5.00 price target on shares of Hoth Therapeutics in a research note on Thursday, December 4th. Finally, Wall Street Zen lowered Hoth Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Hoth Therapeutics has a consensus rating of “Hold” and an average price target of $4.50.

View Our Latest Research Report on Hoth Therapeutics

Hoth Therapeutics Trading Down 1.9%

The firm’s 50 day simple moving average is $1.10 and its 200-day simple moving average is $1.31. The stock has a market capitalization of $16.29 million, a price-to-earnings ratio of -0.99 and a beta of 0.57.

Hoth Therapeutics (NASDAQ:HOTH – Get Free Report) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.20). As a group, equities research analysts predict that Hoth Therapeutics, Inc. will post -1.36 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Lido Advisors LLC acquired a new stake in shares of Hoth Therapeutics in the 3rd quarter valued at approximately $32,000. Kestra Private Wealth Services LLC bought a new stake in Hoth Therapeutics during the third quarter worth $51,000. Virtu Financial LLC bought a new stake in Hoth Therapeutics during the third quarter worth $184,000. Geode Capital Management LLC lifted its stake in Hoth Therapeutics by 8.0% in the second quarter. Geode Capital Management LLC now owns 122,575 shares of the company’s stock valued at $143,000 after acquiring an additional 9,071 shares during the last quarter. Finally, Citadel Advisors LLC bought a new position in shares of Hoth Therapeutics in the 3rd quarter valued at about $232,000. Institutional investors and hedge funds own 7.08% of the company’s stock.

About Hoth Therapeutics

(Get Free Report)

Hoth Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the acquisition, licensing and development of novel therapies for dermatological, central nervous system and other debilitating conditions. The company’s strategy emphasizes in-licensing late preclinical or early clinical assets with promising pharmacological profiles and leveraging formulation science to optimize delivery. Core to its approach is the design of topical and localized administration platforms intended to enhance drug penetration, sustain release and reduce systemic exposure.

Hoth’s development pipeline encompasses multiple candidate programs addressing high-unmet-need areas such as atopic dermatitis, epidermolysis bullosa and oral mucositis.

Recommended Stories